Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

With the notable exceptions of Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY), biotechnology stocks had a rough ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Now, Lilly has reinforced that finding with a strong of other measures, including that 32% of people taking Zepbound were able to lose a quarter of their body weight compared to 16% of the Wegovy ...

Personally, I've been on Zepbound for nearly 10 weeks now and I've lost over 25 pounds thanks to a combination of the injection, diet, exercise and, of course, the advice of my doctor.

IQVIA figures on prescriptions for Zepbound and Wegovy, reported by Reuters, suggest that there were nearly 339,000 scrips for Lilly's product in the week ending 18th April, overtaking Novo ...

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.